Ameriprise Financial Inc. Has $704,000 Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Ameriprise Financial Inc. reduced its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 85,586 shares of the company’s stock after selling 2,006 shares during the period. Ameriprise Financial Inc. owned 0.17% of Aura Biosciences worth $704,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aura Biosciences during the 4th quarter worth about $87,000. Harvest Investment Services LLC bought a new position in shares of Aura Biosciences in the fourth quarter valued at approximately $133,000. AlphaQuest LLC acquired a new stake in shares of Aura Biosciences in the fourth quarter worth $136,000. Intech Investment Management LLC acquired a new stake in shares of Aura Biosciences in the fourth quarter worth $172,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Aura Biosciences by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after buying an additional 5,930 shares during the period. 96.75% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Aura Biosciences

In other news, insider Conor Kilroy sold 7,162 shares of the business’s stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total value of $39,319.38. Following the sale, the insider now owns 179,313 shares in the company, valued at approximately $984,428.37. The trade was a 3.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David Michael Johnson bought 20,000 shares of Aura Biosciences stock in a transaction dated Friday, May 16th. The stock was purchased at an average price of $4.90 per share, for a total transaction of $98,000.00. Following the purchase, the director now directly owns 166,167 shares in the company, valued at $814,218.30. This represents a 13.68% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 9,578 shares of company stock valued at $52,067. Corporate insiders own 5.40% of the company’s stock.

Aura Biosciences Price Performance

AURA opened at $6.16 on Tuesday. The company has a market capitalization of $309.66 million, a P/E ratio of -3.56 and a beta of 0.43. The firm’s fifty day moving average price is $5.63 and its two-hundred day moving average price is $7.17. Aura Biosciences, Inc. has a fifty-two week low of $4.35 and a fifty-two week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.08). On average, equities research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AURA. HC Wainwright raised shares of Aura Biosciences to a “buy” rating and set a $22.00 target price for the company in a research report on Wednesday, May 28th. Citigroup reaffirmed an “outperform” rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Finally, JMP Securities reiterated a “market outperform” rating and set a $19.00 price target on shares of Aura Biosciences in a report on Friday, May 23rd. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $22.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.